These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

92 related items for PubMed ID: 17395409

  • 1. Influence of estrogens and antiestrogens on the expression of selected hormone-responsive genes.
    Sismondi P, Biglia N, Ponzone R, Fuso L, Scafoglio C, Cicatiello L, Ravo M, Weisz A, Cimino D, Altobelli G, Friard O, De Bortoli M.
    Maturitas; 2007 May 20; 57(1):50-5. PubMed ID: 17395409
    [Abstract] [Full Text] [Related]

  • 2. Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin.
    Gielen SC, Burger CW, Kühne LC, Hanifi-Moghaddam P, Blok LJ.
    J Soc Gynecol Investig; 2005 Oct 20; 12(7):e55-67. PubMed ID: 16202921
    [Abstract] [Full Text] [Related]

  • 3. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
    Pink JJ, Jordan VC.
    Cancer Res; 1996 May 15; 56(10):2321-30. PubMed ID: 8625307
    [Abstract] [Full Text] [Related]

  • 4. Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells.
    Wang Z, Kyo S, Maida Y, Takakura M, Tanaka M, Yatabe N, Kanaya T, Nakamura M, Koike K, Hisamoto K, Ohmichi M, Inoue M.
    Oncogene; 2002 May 16; 21(22):3517-24. PubMed ID: 12032853
    [Abstract] [Full Text] [Related]

  • 5. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
    Dardes RC, O'Regan RM, Gajdos C, Robinson SP, Bentrem D, De Los Reyes A, Jordan VC.
    Clin Cancer Res; 2002 Jun 16; 8(6):1995-2001. PubMed ID: 12060645
    [Abstract] [Full Text] [Related]

  • 6. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780).
    Gu Z, Lee RY, Skaar TC, Bouker KB, Welch JN, Lu J, Liu A, Zhu Y, Davis N, Leonessa F, Brünner N, Wang Y, Clarke R.
    Cancer Res; 2002 Jun 15; 62(12):3428-37. PubMed ID: 12067985
    [Abstract] [Full Text] [Related]

  • 7. Gene expression changes induced by estrogen and selective estrogen receptor modulators in primary-cultured human endometrial cells: signals that distinguish the human carcinogen tamoxifen.
    Pole JC, Gold LI, Orton T, Huby R, Carmichael PL.
    Toxicology; 2005 Jan 05; 206(1):91-109. PubMed ID: 15590111
    [Abstract] [Full Text] [Related]

  • 8. Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor.
    Levenson AS, Svoboda KM, Pease KM, Kaiser SA, Chen B, Simons LA, Jovanovic BD, Dyck PA, Jordan VC.
    Cancer Res; 2002 Aug 01; 62(15):4419-26. PubMed ID: 12154049
    [Abstract] [Full Text] [Related]

  • 9. Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells.
    Scafoglio C, Ambrosino C, Cicatiello L, Altucci L, Ardovino M, Bontempo P, Medici N, Molinari AM, Nebbioso A, Facchiano A, Calogero RA, Elkon R, Menini N, Ponzone R, Biglia N, Sismondi P, De Bortoli M, Weisz A.
    J Cell Biochem; 2006 Aug 01; 98(5):1163-84. PubMed ID: 16514628
    [Abstract] [Full Text] [Related]

  • 10. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex.
    Liu H, Lee ES, Deb Los Reyes A, Zapf JW, Jordan VC.
    Cancer Res; 2001 May 01; 61(9):3632-9. PubMed ID: 11325832
    [Abstract] [Full Text] [Related]

  • 11. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N, Boysen B, Jirus S, Skaar TC, Holst-Hansen C, Lippman J, Frandsen T, Spang-Thomsen M, Fuqua SA, Clarke R.
    Cancer Res; 1997 Aug 15; 57(16):3486-93. PubMed ID: 9270017
    [Abstract] [Full Text] [Related]

  • 12. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer.
    Saji S, Kawakami M, Hayashi S, Yoshida N, Hirose M, Horiguchi S, Itoh A, Funata N, Schreiber SL, Yoshida M, Toi M.
    Oncogene; 2005 Jun 30; 24(28):4531-9. PubMed ID: 15806142
    [Abstract] [Full Text] [Related]

  • 13. Molecular identification of potential selective estrogen receptor modulator (SERM) like properties of phytoestrogens in the human breast cancer cell line MCF-7.
    Diel P, Olff S, Schmidt S, Michna H.
    Planta Med; 2001 Aug 30; 67(6):510-4. PubMed ID: 11509969
    [Abstract] [Full Text] [Related]

  • 14. Induction of two estrogen-responsive proteins by antiestrogens in R27, a tamoxifen-resistant clone of MCF7 cells.
    Vignon F, Lippman ME, Nawata H, Derocq D, Rochefort H.
    Cancer Res; 1984 May 30; 44(5):2084-8. PubMed ID: 6713400
    [Abstract] [Full Text] [Related]

  • 15. Selective estrogen receptor modulators prevent neointima formation after vascular injury.
    Savolainen-Peltonen H, Luoto NM, Kangas L, Häyry P.
    Mol Cell Endocrinol; 2004 Nov 30; 227(1-2):9-20. PubMed ID: 15501580
    [Abstract] [Full Text] [Related]

  • 16. Anti-inflammatory effect of selective estrogen receptor modulators (SERMs) in microglial cells.
    Suuronen T, Nuutinen T, Huuskonen J, Ojala J, Thornell A, Salminen A.
    Inflamm Res; 2005 May 30; 54(5):194-203. PubMed ID: 15953991
    [Abstract] [Full Text] [Related]

  • 17. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells.
    Poulin R, Merand Y, Poirier D, Levesque C, Dufour JM, Labrie F.
    Breast Cancer Res Treat; 1989 Oct 30; 14(1):65-76. PubMed ID: 2605344
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparative analyses of mechanistic differences among antiestrogens.
    Wijayaratne AL, Nagel SC, Paige LA, Christensen DJ, Norris JD, Fowlkes DM, McDonnell DP.
    Endocrinology; 1999 Dec 30; 140(12):5828-40. PubMed ID: 10579349
    [Abstract] [Full Text] [Related]

  • 20. Effects of the antiestrogens tamoxifen and raloxifene on the estrogen receptor transactivation machinery.
    Glaeser M, Niederacher D, Djahansouzi S, Hanstein B, Dittrich R, Beckmann MW, Fasching PA, Ackermann S.
    Anticancer Res; 2006 Dec 30; 26(1B):735-44. PubMed ID: 16739346
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.